Workflow
维力医疗(603309) - 2021 Q1 - 季度财报
Well LeadWell Lead(SH:603309)2021-04-26 16:00

Financial Performance - The net profit attributable to shareholders increased by CNY 14.81 million compared to the same period last year, primarily due to lower revenue in the previous year affected by the pandemic[6]. - Operating revenue for the period reached CNY 219.89 million, representing a 40.87% increase from CNY 156.10 million in the same period last year[6]. - The net profit attributable to shareholders was CNY 22.70 million, a significant increase of 187.58% compared to CNY 7.89 million in the previous year[6]. - Basic and diluted earnings per share both increased by 200% to CNY 0.09 from CNY 0.03 in the same period last year[6]. - The company reported a total comprehensive income of CNY 24,826,527.82 for Q1 2021, compared to CNY 9,422,240.21 in Q1 2020[29]. - Net profit for Q1 2021 reached CNY 24,826,527.82, representing a 63.1% increase compared to CNY 9,422,240.21 in Q1 2020[28]. - In Q1 2021, the company's net profit reached CNY 30,026,915.91, a significant increase from CNY 6,500,443.43 in Q1 2020, representing a growth of approximately 362%[32]. - Operating profit for Q1 2021 was CNY 31,813,947.62, compared to CNY 13,803,647.06 in the same period last year, indicating an increase of about 130%[32]. Cash Flow and Investments - The net cash flow from operating activities decreased by 85.61% to CNY 2.39 million from CNY 16.64 million in the same period last year[6]. - Cash flow from operating activities decreased by 85.61% to ¥2,394,893.02 from ¥16,638,447.71, primarily due to increased personnel costs related to sales model adjustments[13]. - The cash flow from investing activities was negative at -¥56,540,363.91, indicating higher expenditures on financial products compared to recoveries[13]. - Investment activities resulted in a net cash outflow of CNY 56,540,363.91 in Q1 2021, compared to a net outflow of CNY 11,690,373.60 in Q1 2020, indicating a worsening investment cash flow situation[35]. - The net cash flow from investing activities was -33,089,148.21 RMB in Q1 2021, compared to -3,455,959.56 RMB in Q1 2020, indicating a significant increase in cash outflow[38]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1.51 billion, a 1.67% increase from CNY 1.49 billion at the end of the previous year[6]. - Current assets totaled ¥404,448,533.52, down from ¥434,941,789.04, indicating a decrease of about 7.7%[20]. - Non-current assets increased to ¥1,109,183,586.33 from ¥1,053,833,439.07, representing a growth of approximately 5.3%[21]. - Total liabilities decreased slightly to ¥343,808,778.81 from ¥344,828,414.89, a reduction of about 0.3%[22]. - The total liabilities decreased to CNY 335,498,639.89 in Q1 2021 from CNY 404,968,381.38 in Q1 2020, a reduction of 17.1%[28]. - Total assets decreased slightly to CNY 1,406,756,539.36 in Q1 2021 from CNY 1,446,199,364.94 in Q1 2020[28]. - The total cash and cash equivalents at the end of Q1 2021 were 30,551,898.21 RMB, down from 104,940,134.27 RMB at the end of Q1 2020, reflecting a decrease of approximately 70%[38]. Equity and Shareholder Information - The weighted average return on equity increased by 1.21 percentage points to 1.98% from 0.77% in the previous year[6]. - The net assets attributable to shareholders increased by 2.00% to CNY 1.16 billion from CNY 1.13 billion at the end of the previous year[6]. - The company reported a total equity of ¥1,169,823,341.04, up from ¥1,143,946,813.22, indicating an increase of about 2.3%[22]. - The company's total equity remained stable at 1,143,946,813.22 RMB as of Q1 2021, with no changes reported compared to the previous period[43]. Research and Development - Research and development expenses increased by 42.20% to ¥11,312,222.86 from ¥7,955,086.12, reflecting the company's commitment to enhancing R&D efforts[13]. - Research and development expenses for Q1 2021 were CNY 11,312,222.86, up 42.6% from CNY 7,955,086.12 in Q1 2020[28]. Government Subsidies - Government subsidies received during the period increased by CNY 2.38 million compared to the same period last year[6]. - The company reported a significant increase in other income, which rose to ¥3,498,664.66, a 343.46% increase from ¥788,945.31, mainly due to higher government subsidies received[13].